Research ArticleCellular and Molecular
In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183
Randy S. Schrecengost, Cecelia L. Green, Yan Zhuang, Staci N. Keller, Ryan A. Smith, Lynn W. Maines and Charles D. Smith
Journal of Pharmacology and Experimental Therapeutics April 2018, 365 (1) 107-116; DOI: https://doi.org/10.1124/jpet.117.245738
Randy S. Schrecengost
Apogee Biotechnology Corporation, Hummelstown, Pennsylvania
Cecelia L. Green
Apogee Biotechnology Corporation, Hummelstown, Pennsylvania
Yan Zhuang
Apogee Biotechnology Corporation, Hummelstown, Pennsylvania
Staci N. Keller
Apogee Biotechnology Corporation, Hummelstown, Pennsylvania
Ryan A. Smith
Apogee Biotechnology Corporation, Hummelstown, Pennsylvania
Lynn W. Maines
Apogee Biotechnology Corporation, Hummelstown, Pennsylvania
Charles D. Smith
Apogee Biotechnology Corporation, Hummelstown, Pennsylvania

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleCellular and Molecular
Dual Targeting GSK3 and CDK9 with Novel ABC1183
Randy S. Schrecengost, Cecelia L. Green, Yan Zhuang, Staci N. Keller, Ryan A. Smith, Lynn W. Maines and Charles D. Smith
Journal of Pharmacology and Experimental Therapeutics April 1, 2018, 365 (1) 107-116; DOI: https://doi.org/10.1124/jpet.117.245738
Research ArticleCellular and Molecular
Dual Targeting GSK3 and CDK9 with Novel ABC1183
Randy S. Schrecengost, Cecelia L. Green, Yan Zhuang, Staci N. Keller, Ryan A. Smith, Lynn W. Maines and Charles D. Smith
Journal of Pharmacology and Experimental Therapeutics April 1, 2018, 365 (1) 107-116; DOI: https://doi.org/10.1124/jpet.117.245738
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement